Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library
CT-996 (RO7795081): what the evidence says
At a glance
What it is: Caution Not a peptide. CT-996 is a once-daily oral small-molecule GLP-1 receptor agonist from Roche (originally Carmot), not an amino-acid chain. It is listed here only because it is sold alongside research peptides. R1, R2
What the evidence says: Unknown three phase 1 trials are registered and two are complete, R1, R2, R3 but a PubMed search on Oct 27, 2026 found no peer-reviewed results. UNVERIFIED any weight-loss figures circulating from company presentations.
Biggest risks: expected GLP-1 class effects (nausea, vomiting); human safety data are not published.
Rating
| Human Human evidence | Very limited: registered phase 1 trials, no published results R1 |
| Animal Animal / lab evidence | Unknown None published that we found |
| Regulatory | Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page R4, R5, R6 · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances) R7 |
| Established human dose | No |
Evidence verdict: Weight loss: Very limited (phase 1 only, no peer-reviewed results found)
This page reports what studies used. It is not dosing advice.
Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source
About the evidence: there is nothing peer-reviewed to grade yet. Everything known publicly comes from the sponsor.
What is it?
Related pages: ct-388, azd5004, semaglutide, orforglipron.
Does it work?
- Unknown Phase 1 in overweight/obesity and type 2 diabetes (n = 94), completed Nov 2025. R1
- Unknown Drug-interaction study (itraconazole, gemfibrozil, cyclosporine), completed. R2
Is it safe?
- Unknown No published safety data.
Pipeline status (investigational)
- Sponsor: Roche (Carmot). R2
- Trials: NCT05814107 (completed) R1; NCT06809608 (completed) R2; NCT07499050, estimated primary completion Jan 2027. R3
- Expected readouts: UNVERIFIED phase 2 plans and dates.
Gray-market vials: extra risks
A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.
Is it legal?
- US: not FDA-approved; no Drugs@FDA application found (openFDA searched Oct 27, 2026).
- Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. R4, R5, R6
- Sport: not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances) R7.
Study details
Study details
These are amounts researchers used, not recommendations.
| Study | People / model | Route | Amount used | Follow-up | Reported | Citation |
|---|---|---|---|---|---|---|
| No published dosing study | — | Oral | — | — | Phase 1 results not peer-reviewed | — |
Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 27, 2026)
- R1 ClinicalTrials.gov NCT05814107, phase 1, overweight/obesity and type 2 diabetes, completed (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT05814107
- R2 ClinicalTrials.gov NCT06809608, phase 1 drug-interaction study, Roche, completed (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT06809608
- R3 ClinicalTrials.gov NCT07499050, phase 1 in Chinese adults, Roche, active (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT07499050
- R4 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
- R5 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
- R6 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- R7 WADA. The 2026 Prohibited List, S0 Non-approved substances. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Disclaimer
This page is for education and harm reduction, not medical advice or a recommendation to use CT-996 (RO7795081). This is an investigational drug. It is available only inside registered clinical trials; products sold online under this name are unregulated. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).